Week of July 21st, 2019 | FDA Sent These Warning Letters to Pharma/Device Companies

We cover three GMP drug warning letters and a warning letter to a large CBD firm for misbranding and distribution of the unapproved new drug. FDA did not agree with the firm’s statement that the product was a dietary supplement.